Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut...

Full description

Bibliographic Details
Main Authors: Ting-Rui Han, Wen-Juan Yang, Qing-Hua Tan, Shuai Bai, Huang Zhong, Yang Tai, Huan Tong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Microbiology
Subjects:
non-alcoholic fatty liver disease
gut microbiota
randomized clinical trial
probiotics
prebiotics
synbiotics
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2022.1004911/full

Similar Items

Similar Items